csDMARDlääkkeistä

csDMARDlääkkeet, or conventional synthetic disease-modifying antirheumatic drugs, are a cornerstone in the management of inflammatory autoimmune diseases, particularly rheumatoid arthritis. These medications work by modulating the immune system to reduce inflammation and slow down or halt the progression of joint damage. Unlike medications that only treat symptoms, csDMARDs target the underlying disease process.

The most common csDMARD is methotrexate, which is often the first-line treatment for rheumatoid arthritis. Other examples include sulfasalazine, hydroxychloroquine, and leflunomide. These drugs are not immediate pain relievers; their effects typically take several weeks or months to become fully apparent. Due to their immunosuppressive nature, csDMARDs can have side effects, which vary depending on the specific drug. Common side effects might include gastrointestinal issues, fatigue, or increased susceptibility to infections. Regular monitoring by a healthcare professional is crucial to manage these potential risks and assess treatment effectiveness. The choice of csDMARD depends on the specific disease, its severity, and individual patient factors. They are often used in combination with other therapies, including nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids for symptom relief, and more recently, with biologic DMARDs for more severe or refractory cases.